Development of Potency Assays Based on Transgene Protein Expression for Cell Therapy Product Release Testing

PROVEN INTELLIGENCE ACCELERATING NEXT-GENERATION THERAPIES

Development of Potency Assays Based on Transgene Protein Expression for Cell Therapy Product Release Testing

Potency Assays for Cell Therapy Release Testing via Transgene Expression

CELL & GENE | RNA | BIOLOGICS

Frequently Asked Questions (FAQ)

    What is the primary challenge in developing a potency assay based on transgene protein expression?

    A: The main challenge is establishing a definitive correlation between the quantified level of protein expression and the cell therapy product’s intended biological mechanism of action (MoA). The assay must not only measure the protein but also serve as a reliable surrogate for clinical efficacy.

    Which analytical platforms are best suited for quantifying transgene protein expression in a GxP environment?

    A: The choice depends on the target protein’s characteristics and required sensitivity. Mass spectrometry (LC-MS/MS) offers high specificity and multiplexing capabilities, while ligand binding assays (e.g., ELISA) provide high throughput and sensitivity for well-characterized proteins with available reagents.

    How do you ensure a potency assay is stability-indicating for lot release?

    A: A stability-indicating method is confirmed by demonstrating that the assay can detect changes in product potency over time and under stress conditions (e.g., temperature excursions). This involves analyzing degraded samples to prove the assay accurately reflects a loss of the protein’s functional activity or expression level.

    What are the regulatory expectations for these assays in the UK?

    A: The UK’s regulatory body, the MHRA, expects potency assays to be well-characterized, validated, and directly relevant to the product’s MoA. The method must be robust and suitable for its intended purpose within a GxP framework, with clear specifications for product release.

Developing a robust, GxP-compliant potency assay based on transgene protein expression is a core Chemistry, Manufacturing, and Controls (CMC) requirement for advancing cell therapies. This process requires the selection of a suitable analytical platform, such as mass spectrometry, to quantitatively measure the therapeutic protein. The resulting data must be directly correlated with the product’s mechanism of action to satisfy regulatory expectations for lot release testing.

Defining Potency Through Protein Expression

For many advanced cell therapy products, the intended therapeutic effect is directly mediated by a protein expressed from a genetic payload. Consequently, a well-developed potency assay that quantifies this transgene protein expression provides a direct and scientifically sound measure of the product’s biological activity. This approach moves beyond simple cell viability metrics to assess the functional attribute that drives the desired clinical outcome.

The development of such an assay requires a deep understanding of the protein’s biology and the selection of an appropriate analytical technology. Key considerations include:

  • Specificity: The method must distinguish the therapeutic protein from endogenous variants or related isoforms.

  • Sensitivity: The assay must possess a limit of quantification sufficient to measure expression at clinically relevant levels.

  • Matrix Effects: The assay must perform reliably in the presence of complex biological matrices.

  • Correlation to MoA: The measured protein level must have a clear, documented link to the product’s functional activity.

A 3D rendering of Y-shaped antibody molecules against a blue, abstract background.

A close-up of a scientist in a lab, wearing blue gloves and examining the results of a gel electrophoresis or Western blot.

Quantitative Bioanalytical Strategies

The successful quantification of transgene expression hinges on sophisticated bioanalytical techniques. As demonstrated in preclinical gene therapy programs, developing species-specific mass spectrometry methods is an effective strategy for accurately measuring therapeutic protein levels, particularly when dealing with robust or non-linear expression patterns in target tissues (PMID: 37891254). This principle of tailored method development is directly applicable to cell therapy release testing.

At our >100,000 sq ft GxP-compliant facility, we focus on a phased approach to assay development. This ensures the final method is fit-for-purpose as part of a CMC package designed for an 18-24 month IND timeline. Since 2019, programs we have supported have achieved a 100% IND success rate, a testament to this rigorous methodology (Franklin Biolabs brand launched in 2024).

From Development to Lot Release

A potency assay is an integral component of the product’s quality control strategy. The assay must be validated according to ICH guidelines and proven to be robust and transferable to a quality control environment.

The validation package will demonstrate the assay’s:

  • Accuracy

  • Precision (Repeatability and Intermediate Precision)

  • Linearity and Range

  • Specificity

  • Robustness

This comprehensive validation ensures that the assay provides consistent and reliable data for every manufactured lot, giving confidence to both developers and regulatory bodies like the MHRA.

Scientific Process Diagram

This content is for informational purposes. For guidance specific to your therapeutic program, please contact our team for a consultation.

Explore More Capabilities